In a 3-year-old child (208) with a malignant neuroblastoma with elevated levels of plasma GRP and pancreastatin, there was a 30–60% decrease in the high levels with treatment with octreotide, leading the authors to suggest that assessment of plasma GRP and other peptides might be useful markers of response to treatment. This evidence concerns the gene GRP and neuroblastoma.